A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Status:
COMPLETED
Trial end date:
2025-08-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.